News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • No new articles were published in the past hour across markets, economy, or geopolitics.
  • No market-moving economic data or central-bank comments appeared in the feed this hour.
  • There were no major corporate earnings, M&A announcements, or regulatory actions reported.
  • No fresh geopolitical incidents or significant policy shifts were recorded in the last hour.
  • Newsflow absence suggests limited catalyst-driven volatility for markets in the near term.
  • Traders likely face a quiet hour with price action driven by existing positions rather than new information.

Latest Articles

OrthoPediatrics Expands Its Lower Extremity Bracing Portfolio with the Launch of OPSB® Knee 'TractorFIX

OrthoPediatrics Expands Its Lower Extremity Bracing Portfolio with the Launch of OPSB® Knee 'TractorFIX

OrthoPediatrics Corp. announced the launch of the OPSB® Knee 'TractorFIX, a pioneering pediatric bracing solution designed to manage knee contractures in young patients undergoing tibial treatment with external fixators. This new product expands their specialty bracing portfolio, offering a standardized alternative to custom-built solutions and int…

Zenas BioPharma Announces Upcoming Presentations of Orelabrutinib Data in Relapsing Remitting Multiple Sclerosis, Clinical Trial Designs in Progressive Multiple Sclerosis and Other Multiple Sclerosis Portfolio Data at MSToronto2026

Zenas BioPharma Announces Upcoming Presentations of Orelabrutinib Data in Relapsing Remitting Multiple Sclerosis, Clinical Trial Designs in Progressive Multiple Sclerosis and Other Multiple Sclerosis Portfolio Data at MSToronto2026

Zenas BioPharma announces presentations of clinical data for Orelabrutinib and Obexelimab across multiple sclerosis subtypes at MSToronto2026 conference, highlighting progress in late-stage trials and potential new therapies for progressive MS with unmet needs.

OR Royalties Announces Preliminary Q3 2026 GEO Deliveries

OR Royalties Announces Preliminary Q3 2026 GEO Deliveries

OR Royalties Inc. announced its preliminary third quarter 2026 results, earning 20,237 gold equivalent ounces and generating revenues of $90.2 million with a high cash margin of 96.8%. The company also completed a $15 million royalty acquisition during the quarter and maintains a strong cash position of $76.7 million. The revolving credit facility …

Marex announces changes to Group Board

Marex announces changes to Group Board

Marex Group Limited announced that Robert Pickering has stepped down as Chair of the Board after overseeing significant growth, including the company's IPO on Nasdaq in April 2024. John Pietrowicz, former CFO of CME Group and current Board member, has succeeded him as Chair, bringing valuable expertise in financial markets and mergers and acquisiti…

Arvinas Shares Novel Oculomotor and Biomarker Data from Phase 1 Clinical Trial of ARV-102 in Patients with Parkinson’s Disease

Arvinas Shares Novel Oculomotor and Biomarker Data from Phase 1 Clinical Trial of ARV-102 in Patients with Parkinson’s Disease

Arvinas, Inc. announced final data from its Phase 1 clinical trial of ARV-102, a PROTAC degrader targeting LRRK2, in Parkinson’s disease patients. The trial demonstrated that ARV-102 crosses the blood-brain barrier, reduces LRRK2 protein levels in cerebrospinal fluid, and leads to improvements in oculomotor function and biomarkers related to neurod…

BillionToOne’s Tissue-Free Northstar Response® Demonstrates On-Par to Superior Cancer Treatment Monitoring vs. Tumor-Informed Assay, New Peer-Reviewed Study Finds

BillionToOne’s Tissue-Free Northstar Response® Demonstrates On-Par to Superior Cancer Treatment Monitoring vs. Tumor-Informed Assay, New Peer-Reviewed Study Finds

BillionToOne announced the publication of a real-world peer-reviewed study demonstrating that its tissue-free Northstar Response liquid biopsy assay tracks cancer treatment response as effectively or better than a commercially available tumor-informed assay, without needing tumor tissue sequencing. The study showed high concordance in measuring tum…

VERAXA Biotech Provides Overview on Implementation of  FDA-Aligned Human-Relevant Models into R&D Strategy

VERAXA Biotech Provides Overview on Implementation of FDA-Aligned Human-Relevant Models into R&D Strategy

VERAXA Biotech AG updates on implementing New Approach Methodologies (NAMs) aligned with FDA guidelines into its R&D, enabling faster clinical progression and significantly decreasing animal testing. Utilizing advanced human-relevant models such as 3D spheroids and patient-derived xenografts, VERAXA demonstrates improved preclinical predictivity an…

Cadrenal Therapeutics Retains Tungsten Advisors to Lead Formal Strategic Process to Maximize Value of its Orphan Thrombo-Inflammatory Therapeutics

Cadrenal Therapeutics Retains Tungsten Advisors to Lead Formal Strategic Process to Maximize Value of its Orphan Thrombo-Inflammatory Therapeutics

Cadrenal Therapeutics has engaged Tungsten Advisors to lead a formal strategic process aimed at exploring various transactions to maximize the value of its orphan thrombo-inflammatory therapeutics portfolio. The company’s pipeline has reached significant clinical and regulatory milestones, including FDA alignment on a Phase 3 pathway for lead candi…

Rocket Lab Poised to Break Higher — A Tactical Long with Defined Risk

Rocket Lab Poised to Break Higher — A Tactical Long with Defined Risk

Rocket Lab (RKLB) is showing improving top-line momentum, bullish technicals and a low-debt balance sheet while preparing transformational M&A and product catalysts. We outline a concrete trade: entry at $74.50, target $95.00, stop loss $64.00 over a mid-term horizon (45 trading days). The trade balances upside from launch cadence, Space Systems gr…

Alpha Compute’s GAMEE Reports Q3 Record 94% YoY Growth, Reaches Monthly Profitability with over 118 million game-plays, Expands Into AI-Powered Consumer Applications

Alpha Compute’s GAMEE Reports Q3 Record 94% YoY Growth, Reaches Monthly Profitability with over 118 million game-plays, Expands Into AI-Powered Consumer Applications

Alpha Compute Corp.'s subsidiary GAMEE reported a record 94% year-over-year revenue growth in Q3 2026, reaching $1.71 million and achieving monthly profitability for the first time. The company has expanded into AI-powered consumer applications, leveraging its gaming expertise and AI capabilities, with initial AI product launches expected in Q4 202…

Eli Lilly: When Clinical Dominance Meets Valuation Pressure

Eli Lilly: When Clinical Dominance Meets Valuation Pressure

Eli Lilly has built a rare position of strength in obesity and diabetes drugs, but that dominance carries valuation risk and exposure to payor pushback and competitive launches. We outline a short trade with a clear entry, stop and target and explain the fundamental and catalyst-driven path to a meaningful pullback over the next 180 trading days.

Radware Named a Leader in 2026 IDC MarketScape for Worldwide Web Application and API Protection Platforms

Radware Named a Leader in 2026 IDC MarketScape for Worldwide Web Application and API Protection Platforms

Radware (NASDAQ: RDWR), a leader in AI and application security solutions, was named a Leader in the IDC MarketScape for Worldwide Web Application and API Protection Platforms for 2026. The company is praised for its innovative AI-based security engine and the introduction of its AI Xploit Shield, which delivers advanced, automated threat detection…

Gogoro Inc. Announces US$61.8 Million New Round of Equity Investments

Gogoro Inc. Announces US$61.8 Million New Round of Equity Investments

Gogoro Inc., a Nasdaq-listed leader in battery-swapping technology and electric mobility, announced a $61.8 million new round of equity investments from strategic investors including directors and related entities. The issuance of 24.9 million shares at $2.48 each aims to strengthen its capital base, support ongoing business development, and fulfil…